Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.

Brett A KingArash MostaghimiYutaka ShimomuraAbraham ZlotogorskiGwang-Seong ChoiUlrike Blume-PeytaviThierry PasseronKatrin HolzwarthYves DutroncJill McCollamFan Emily YangSarah StanleyWen-Shuo WuRodney Sinclair

Published in: The British journal of dermatology (2023)

This integrated safety analysis in patients with severe AA is consistent with the overall safety profile of baricitinib. Some differences with atopic dermatitis were noted that may be attributable to the disease characteristics of AA.

Keyphrases

atopic dermatitis
early onset